The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disparate outcomes among Latino and non-Hispanic White (NHW) patients with metastatic clear cell renal cell carcinoma (mccRCC).
 
Sharon Choi
No Relationships to Disclose
 
John Bliamptis
No Relationships to Disclose
 
Justine Panian
No Relationships to Disclose
 
Regina Barragán Carrillo
No Relationships to Disclose
 
Skylar Reid
No Relationships to Disclose
 
Thomas O'Keefe
No Relationships to Disclose
 
Kripa Guram
No Relationships to Disclose
 
Suzanna Lee
No Relationships to Disclose
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Brent Shane Rose
No Relationships to Disclose
 
Aditya Bagrodia
Consulting or Advisory Role - Veracyte
 
Ithaar Derweesh
No Relationships to Disclose
 
Rana R. McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)